調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Orphan Drugs Market Report 2018-2028 : Forecasts and Analysis by Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular, Nephrology and Ophthalmology), Drug Class (Biologic, Small Molecule) & by Region Plus Analysis of Leading Companies

希少疾病用医薬品 (オーファンドラッグ)の世界市場2018-2028

◆タイトル：Orphan Drugs Market Report 2018-2028 : Forecasts and Analysis by Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular, Nephrology and Ophthalmology), Drug Class (Biologic, Small Molecule) & by Region Plus Analysis of Leading Companies
◆商品コード：VGAIN803040
◆調査・発行会社：visiongain
◆発行日：2018年1月
◆ページ数：173
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療・製薬
◆販売価格オプション（消費税別）
Sigle UserGBP3,499 ⇒換算￥0見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算￥0見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算￥0見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

visiongain社が発行した当調査レポートでは、希少疾病用医薬品 (オーファンドラッグ)の世界市場について調査・分析し、希少疾病用医薬品 (オーファンドラッグ)の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・希少疾病用医薬品(オーファンドラッグ) のイントロダクション
・希少疾病用医薬品(オーファンドラッグ)のトップ販売概要2016
・世界における希少疾病用医薬品(オーファンドラッグ)市場2018-2028
・希少疾病用医薬品(オーファンドラッグ)市場：治療薬クラス別
・主要国における市場予測2018-2028
・世界における希少疾病用医薬品(オーファンドラッグ)市場における主要企業2016
・世界における希少疾病用医薬品(オーファンドラッグ)市場の品質分析
・エグゼクティブサマリー・提言
・用語集

The Global Orphan Drugs market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.

Lastly, the study of the pathogenesis of disease at genetic and molecular level studies have led to the discovery of new targets for therapy and producing disease modifying drugs.

Orphan Drugs Market Report 2018-2028

Report highlights

• 149 quantitative tables, charts, and graphs across 173 pages

• Global Orphan Drugs market outlook and analysis from 2018-2028

• Global Orphan Drugs submarket forecasts and analysis from 2018-2028
• Oncology
• Alimentary Tract & Metabolism
• Hormonal Disorders & Haematology
• Neuroscience
• Respiratory
• Cardiovascular
• Nephrology

• Key National Orphan Drugs market forecasts 2018-2028
• US forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• Japan forecast 2018-2028
• Singapore forecast 2018-2028
• South Korea forecast 2018-2028
• Brazil forecast 2018-2028
• Russia forecast 2018-2028
• China forecast 2018-2028
• Brazil forecast 2018-2028

【レポートの目次】

1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Introduction to Orphan Drug Designation
2.1 US Orphan Drug Designation
2.2 Europe Orphan Drug Designation
2.3 Japan Orphan Drug Designation
2.4 Key Feature of Orphan Drug Designation
2.5 Orphan Indication and Prevalence
2.6 Orphan Drug Development Procedure versus Standard Drug Development Procedure
2.7 Development Time: Orphan Drug vs Standard Drug
2.8 Difference between Orphan Drug and Standard Drug

3. Overview on Top Selling Orphan Drugs 2016
3.1 Top Selling Orphan Drugs 2016
3.2 Rituxan
3.3 Revlimid
3.4 Opdivo
3.5 Soliris
3.6 Imbruvica
3.7 Keytruda
3.8 Yervoy
3.9 Orkambi
3.10 Darzalex
3.11 List of Orphan Designated Drug from 2014-2016
3.12 List of Orphan Drug Designation Pipeline

4. Global Orphan Drug Designation Market 2018-2028
4.1 Global Orphan Drug Designation Market 2017
4.2 Market Segmentation by Therapeutic Class 2017
4.3 Oncology
4.3.1 Market Size and Forecast
4.4 Alimentary Tract & Metabolism
4.4.1 Market Size and Forecast
4.5 Hormonal Disorders and Haematology
4.5.1 Market Size and Forecast
4.6 Neuroscience
4.6.1 Market Size and Forecast
4.7 Respiratory
4.7.1 Market Size and Forecast
4.8 Cardiovascular
4.8.1 Market Size and Forecast
4.9 Nephrology and Ophthalmology
4.9.1 Market Size and Forecast

5. Orphan Drug Market by Drug Class
5.1 Market Segmentation by Biologic vs Small Molecule 2017
5.2 Biologic Drug
5.2.1 Market Size and Forecast
5.3 Small Molecule Drug
5.3.1 Market Size and Forecast

6. Leading National Markets Forecast 2018-2028
6.1 Geographical Breakdown of Global Orphan Drug Designation Market, 2017
6.1.1 Region-wise Breakdown of Global Orphan Drug Drugs Market, 2017
6.1.2 Country-wise Breakdown of Global Anti-obesity Drugs Market, 2017
6.1.3 Region-wise Forecast of Global Orphan Drugs Designation Market, 2017-2028
6.2 Orphan Drug Designation Market in the US, 2017
6.2.1 Orphan Drug Designation Activity in the US
6.2.2 FDA’s Orphan Drug Modernization Plan
6.2.3 Market Forecast of the US, 2017-2027
6.2.4 List of Drugs Approved in 2016 by FDA
6.3 Orphan Drug Designation Market in the EU5 Region, 2017
6.3.1 Orphan Applications Figures 2000-2016
6.3.2 Orphan Drug Designation Market Forecast of the EU5 Countries, 2018-2028
6.3.3 The UK
6.3.4 Germany
6.3.5 France
6.3.6 Italy
6.3.7 Spain
6.3.8 List of Drugs Approved in 2016 by European Medicine Agency
6.4 Orphan Drug Designation Market in Japan, 2017
6.4.1 New Orphan Drugs approved in Japan in 2016
6.5 Orphan Drug Designation Market in South Korea, 2017
6.6 Orphan Drug Designation Market in Singapore, 2017
6.7 Orphan Drug Designation Market Forecast of the BRIC Countries
6.7.1 Market Forecast of the BRIC Countries
6.7.2 Orphan Drug Designation Market in Brazil, 2017
6.7.3 Orphan Drug Designation Market in Russia, 2017
6.7.4 Orphan Drug Designation Market in India, 2017
6.7.5 Orphan Drug Designation Market in China, 2017

7. Leading Companies in Global Orphan Drug Designation Market, 2016
7.1 Roche
7.2 Celgene
7.3 Bristol-Myers Squibb
7.4 Novartis
7.5 Amgen
7.6 Merck
7.7 Pfizer
7.8 Other Prominent Vendors in Orphan Drug Designation market

8. Qualitative Analysis of the Global Orphan Drugs Designation Market
8.1 SWOT Analysis, 2016
8.2 Overall Global Orphan Drug Designation Market Drivers, Restraints and Trends
8.2.1 Increased Investment in Orphan Drugs from Companies
8.2.2 Opportunities from the Long Pipeline Will Drive Growth
8.3 Restraints on Growth in the Orphan Drug Designation Market.
8.3.1 Treatment Unavailability
8.3.2 Low Awareness
8.3.3 Regulatory Challenge
8.3.4 Patent Expirations
8.4 Trends on Growth in the Orphan Drug Designation Market
8.4.1 Mergers and Acquisitions
8.4.2 High Pricing
8.5 Pricing and Reimbursement Overview
8.5.1 Payers Perspective

9. Executive Summary and Recommendations

10. Glossary
Visiongain Report Sales Order Form
Associated Visiongain Reports
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Figures
Figure 2.1 Development Time: Orphan Drug vs Standard Drug
Figure 4.1 Global Orphan Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%)
Figure 4.2 Global Orphan Drugs Market Segmentation by Therapeutic Class, Market Share 2017 (%)
Figure 4.3 Global Oncology Market Forecast 2017-2028: Revenue ($b), AGR (%)
Figure 4.4 Global Alimentary tract and Metabolism Market Forecast 2017-2028: Revenue ($bn), AGR (%)
Figure 4.5 Global Hormonal Disorders and Haematology Drug Market Forecast 2017-2028: Revenue ($b), AGR (%)
Figure 4.6 Global Neuroscience Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%)
Figure 4.7 Global Respiratory Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%)
Figure 4.8 Global Cardiovascular Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%)
Figure 4.9 Global Nephrology and Ophthalmology Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%)
Figure 4.10 Global Orphan Drugs Market by Therapeutic Class: Market Share Forecast 2017-2028 (%)
Figure 4.11 Global Orphan Drugs Market by Therapeutic Class 2018 (%)
Figure 4.12 Global Orphan Drugs Market by Therapeutic Class 2023 (%)
Figure 4.13 Global Orphan Drugs Market by Therapeutic Class 2028 (%)
Figure 5.1 Global Orphan Drugs Market Segmentation by Biologic vs Small Molecule, Market Share 2017 (%)
Figure 5.2 Global Biologic Orphan Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Figure 5.3 Global Small Molecule Orphan Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Figure 5.4 Global Orphan Drugs Market Segmentation by Biologic vs Small Molecule Forecast 2017-2028 (%)
Figure 5.5 Global Orphan Drugs Market Segmentation by Biologic vs Small Molecule Forecast 2018 (%)
Figure 5.6 Global Orphan Drugs Market Segmentation by Biologic vs Small Molecule Forecast 2023 (%)
Figure 5.7 Global Orphan Drugs Market Segmentation by Biologic vs Small Molecule Forecast 2028 (%)
Figure 6.1 Global Orphan Drugs Market Segmentation by Region/Country
Figure 6.2 Global Orphan Drugs Market by Region: Revenue ($bn)
Figure 6.3 Global Orphan Drugs Market by Region: Market Share 2017 (%)
Figure 6.4 Global Orphan Drugs Market by Country: Revenue ($bn)
Figure 6.5 Global Orphan Drugs Market by Country: Market Share (%)
Figure 6.6 Global Orphan Drugs Market Forecast by Region 2017, 2023, 2028: Revenue ($bn)
Figure 6.7 Global Orphan Drugs Market by Region: 2017-2028(%)
Figure 6.8 Global Orphan Drug Designation Market by Region: Market Share Forecast 2017-2028 (%)
Figure 6.9 Global Orphan Drug Designation Market by Region: Market Share Forecast 2017 (%)
Figure 6.10 Global Orphan Drug Designation Market by Region: Market Share Forecast 2023 (%)
Figure 6.11 Global Orphan Drug Designation Market by Region: Market Share Forecast 2028 (%)
Figure 6.12 Orphan Drug Designation Market in the US: 2017 Revenue ($m), Market Share %
Figure 6.13 Orphan Drug Designation Market Forecast in the US 2017-2028: Revenue ($bn), AGR (%)
Figure 6.14 Orphan Drug Designation Market in the EU5 2017: Global Market Share (%)
Figure 6.15 Orphan Drug Designation Market in the EU5 Countries 2017: Market Share (%)
Figure 6.16 Orphan Drug Designation Market Forecast in the EU5 2017-2028: Revenue ($bn), AGR (%)
Figure 6.17 Orphan Drug Designation Market Forecast by EU5 Region: Global Market Share 2017(%)
Figure 6.18 Orphan Drug Designation Market Forecast by EU5 Region: Global Market Share 2028(%)
Figure 6.19 Orphan Drug Designation Market Forecast by EU5 Region: Market Share 2017(%)
Figure 6.20 Orphan Drug Designation Market Forecast by EU5 Region: Market Share 2023(%)
Figure 6.21 Orphan Drug Designation Market Forecast by EU5 Region: Market Share 2028(%)
Figure 6.22 Orphan Drug Designation Market Forecast by EU5 Region: AGR 2017-2028 (%)
Figure 6.23 Orphan Drug Designation Market Forecast in the UK: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Figure 6.24 Orphan Drug Designation Market Forecast in Germany: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Figure 6.25 Orphan Drug Designation Market Forecast in France: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Figure 6.26 Orphan Drug Designation Market Forecast in the Italy: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Figure 6.27 Orphan Drug Designation Market Forecast in the Spain: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Figure 6.28 Orphan Drug Designation Market Forecast in the Japan 2017-2028: Revenue ($bn), AGR (%)
Figure 6.29 Orphan Drug Designation Market Forecast in the South Korea: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Figure 6.30 Orphan Drug Designation Market Forecast in Singapore: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Figure 6.31 Orphan Drug Designation Market in the BRIC Region: Global Market Share 2017(%)
Figure 6.32 Orphan Drug Designation Market in the BRIC Region: Global Market Share 2023(%)
Figure 6.33 Orphan Drug Designation Market in the BRIC Region: Global Market Share 2028(%)
Figure 6.34 Orphan Drug Designation Market in the BRIC Countries 2017: Market Share (%)
Figure 6.35 Orphan Drug Designation Market in the BRIC Countries 2023: Market Share (%)
Figure 6.36 Orphan Drug Designation Market in the BRIC Countries 2028: Market Share (%)
Figure 6.37 Orphan Drug Designation Market Forecast by BRIC: AGR 2017-2028 (%)
Figure 6.38 Orphan Drug Designation Market Forecast by BRIC: AGR 2017-2028 ($bn)
Figure 6.39 Orphan Drug Designation Market Forecast in the Brazil: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Figure 6.40 Orphan Drug Designation Market Forecast in the Russia: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Figure 6.41 Orphan Drug Designation Market Forecast in the India: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Figure 6.42 Orphan Drug Designation Market Forecast in the China: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Figure 7.1 Top Selling Orphan Drugs of Roche 2016 in percent (%)
Figure 7.2 Top Selling Orphan Drugs of Roche 2016 vs 2015 ($mn)
Figure 7.3 Top Selling Orphan Drugs of Celgene 2016 in percent (%)
Figure 7.4 Top Selling Orphan Drugs of Celgene 2016 vs 2015 ($mn)
Figure 7.5 Top Selling Orphan Drugs of Bristol-Myers Squibb 2016 in percent (%)
Figure 7.6 Top Selling Orphan Drugs of Bristol-Myers Squibb 2016 vs 2015 ($mn)
Figure 7.7 Top Selling Orphan Drugs of Novartis 2016 in percent (%)
Figure 7.8 Top Selling Orphan Drugs of Novartis 2016 vs 2015 ($mn)
Figure 7.9 Top Selling Orphan Drugs of Amgen 2016 in percent (%)
Figure 7.10 Top Selling Orphan Drugs of Amgen 2016 vs 2015 ($mn)
Figure 7.11 Pfizer: Sales by Geography 2016
Figure 8.1 SWOT Analysis of the Global Orphan Drugs Market
Figure 9.1 Global Orphan Drugs Market Forecast 2016-2027: Revenue ($bn), AGR (%)

List of Tables
Table 2.1 Key Features of Orphan Drug Designation
Table 2.2 Orphan Indications and Prevalence
Table 2.2 Orphan Indications and Prevalence (Continued)
Table 2.3 Difference between Orphan Drugs and Standard Drugs
Table 3.1 Top Selling Orphan Drugs 2016
Table 3.2 List of Orphan Designated Drug from 2014-2016
Table 3.2 List of Orphan Designated Drug from 2014-2016 (Continued)
Table 3.2 List of Orphan Designated Drug from 2014-2016 (Continued)
Table 3.3 Orphan Drug Pipeline 2016
Table 3.3 Orphan Drug Pipeline 2016 (Continued)
Table 3.3 Orphan Drug Pipeline 2016 (Continued)
Table 4.1 Global Orphan Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.2 Global Orphan Drugs Market Segmentation: Revenue ($bn), and Market Share (%), 2017
Table 4.3 Global Oncology Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.4 Global Alimentary tract and Metabolism Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.5 Global Hormonal Disorders and Haematology Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.6 Global Neuroscience Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.7 Global Respiratory Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.8 Global Cardiovascular Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.9 Global Nephrology and Ophthalmology Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.10 Global Orphan Drug Designation Market Segmentation by Therapeutic Class Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.11 Global Orphan Drugs Market by Therapeutic Class: Market Share Forecast 2017-2028 (%)
Table 5.1 Key Features of Biological and Small Molecule Drugs
Table 5.2 Global Biologic Orphan Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 5.3 Global Small Molecule Orphan Drugs Market Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 5.4 Global Orphan Drugs Market Segmentation by Biologic vs Small Molecule Forecast 2017-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 5.5 Global Orphan Drugs Market Segmentation by Biologic vs Small Molecule Forecast 2017-2028(%)
Table 6.1 Global Orphan Drugs Market Segmentation by Region: Revenue ($bn), and Market Share (%), 2017
Table 6.2 Global Orphan Drugs Market by Country: Revenue ($bn), and Market Share (%), 2017
Table 6.3 Global Orphan Drugs Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Table 6.4 Global Orphan Drugs Market by Region: AGR 2016-2027 (%)
Table 6.5 Global Orphan Drugs Market by Region: Market Share Forecast 2017-2028 (%)
Table 6.7 Orphan Drugs Market Forecast in the US: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Table 6.8 List of Drugs Approved in 2016 by FDA
Table 6.8 List of Drugs Approved in 2016 by FDA (Continued)
Table 6.8 List of Drugs Approved in 2016 by FDA (Continued)
Table 6.8 List of Drugs Approved in 2016 by FDA (Continued)
Table 6.8 List of Drugs Approved in 2016 by FDA (Continued)
Table 6.8 List of Drugs Approved in 2016 by FDA (Continued)
Table 6.9 Orphan Drugs in the EU% Region 2016, Revenue ($bn) and Market Share (%)
Table 6.10 EU Orphan Applications 2000-2016
Table 6.11 Orphan Drug Designation Market Forecast in EU5: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.12 Orphan Drug Designation Market Forecast in EU5 Region: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.13 Orphan Drug Designation Market by EU Region: Market Share Forecast 2017-2028 (%)
Table 6.14 Orphan Drug Designation Market Forecast by EU5 Region: AGR 2017-2028 (%)
Table 6.15 Orphan Drug Designation Market Forecast in the UK: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Table 6.17 Orphan Drug Designation Market Forecast in Germany: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.18 Orphan Drug Designation Market Forecast in France: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Table 6.19 Orphan Drug Designation Market Forecast in the Italy: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.20 Orphan Drug Designation Market Forecast in the Spain: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.21 List of Drugs Approved in 2016 by European Medicine Agency
Table 6.21 List of Drugs Approved in 2016 by European Medicine Agency (Continued)
Table 6.22 Orphan Drug Designation Market Forecast in Japan: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.23 Orphan Drug Designation Market Forecast in South Korea: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.24 Orphan Drug Designation Market Forecast in Singapore: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.25 BRIC Orphan Drug Market Snapshot 2016, Revenue ($m) & Market Share (%)
Table 6.26 Orphan Drug Designation Market Forecast by BRIC Region: AGR 2017-2028 (%)
Table 6.27 Global Orphan Drugs Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%),2016-2027
Table 6.28 Orphan Drug Designation Market Forecast in Brazil: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.29 Orphan Drug Designation Market Forecast in Russia: Revenue ($bn), AGR (%), CAGR (%),2017-2028
Table 6.30 Orphan Drug Designation Market Forecast in India: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.31 Orphan Drug Designation Market Forecast in China: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.1 Roche: Overview 2016
Table 7.2 Bristol-Myers Squibb: Overview 2016
Table 7.3 Novartis: Overview 2016
Table 7.4 Amgen: Overview 2016
Table 7.5 Merck: Overview 2016
Table 7.6 Pfizer: Overview 2016
Table 7.7 Other Prominent Vendors in Orphan Drug Designation market
Table 7.7 Other Prominent Vendors in Orphan Drug Designation market (Continued)
Table 7.7 Other Prominent Vendors in Orphan Drug Designation market (Continued)
Table 7.7 Other Prominent Vendors in Orphan Drug Designation market (Continued)
Table 7.7 Other Prominent Vendors in Orphan Drug Designation market (Continued)



★調査レポート[希少疾病用医薬品 (オーファンドラッグ)の世界市場2018-2028] ( Orphan Drugs Market Report 2018-2028 : Forecasts and Analysis by Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular, Nephrology and Ophthalmology), Drug Class (Biologic, Small Molecule) & by Region Plus Analysis of Leading Companies / VGAIN803040) 販売に関する免責事項
[希少疾病用医薬品 (オーファンドラッグ)の世界市場2018-2028] ( Orphan Drugs Market Report 2018-2028 : Forecasts and Analysis by Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular, Nephrology and Ophthalmology), Drug Class (Biologic, Small Molecule) & by Region Plus Analysis of Leading Companies / VGAIN803040) についてEメールでお問い合わせ
◆関連調査資料◆
  • 麻酔薬 の世界市場2018-2028
    VGAIN803047 / visiongain / 2018年2月 / visiongain社が発行した当調査レポートでは、麻酔薬 の世界市場について調査・分析し、麻酔薬 の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・麻酔薬のイントロダクション ・世界における麻酔薬市場のイントロダクション ・世界における麻酔薬市場予測2018-2028 ・世界における麻酔薬市場予測：種類別2018-2028 ・世界における麻酔薬市場予測：投与経路2018-2028 ・世界における麻酔薬地域と国別市場2018-2028...The global anaesthesia drugs market is expected to reach $10.5bn in 2022 and is estimated to grow at a CAGR of 3.6% from 2017 to 2028. The local anaesthesia segment accounted for the largest share in the anaesthesia drugs market and is also projected to grow at the highest CAGR during the forecast period owing to its large application in surgeries, less adverse effects, and high adoption rate. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 172-page report you will receive 104...
  • 産業用制御システム (ICS) の世界市場2018-2028
    VGAIN803012 / visiongain / 2018年1月 / visiongain社が発行した当調査レポートでは、産業用制御システム (ICS) の世界市場について調査・分析し、産業用制御システム (ICS) の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・産業用制御システム(ICS)市場のイントロダクション ・世界における産業用制御システム(ICS)市場2018–2028 ・世界における産業用制御システム(ICS)市場：構成要素別2018-2028 ・世界における産業用制御システム(ICS)市場：ソリューション別2018-2028...The industry developments at the HANNOVER MESSE 2017 trade fair has led Visongain to publish this timely report. The $126.2 Bn industrial control system market is expected to flourish in the next few years because of increasing adoption industry 4.0 and penetration across multiple industry verticals with high rates in biotechnology and pharmaceutical industries are expected to feed through in the latter part of the decade driving growth to new heights. If you want to be part of this growing industry, then read on to discover how you can maximise your investment potential. Report highlights • 177 Quantitative Tables, Charts,...
  • 自動車道路利用料の従量型課金 (PAYG：Pay As You Go) の世界市場2018-2028
    VGAIN803004 / visiongain / 2018年1月 / visiongain社が発行した当調査レポートでは、自動車道路利用料の従量型課金 (PAYG：Pay As You Go) の世界市場について調査・分析し、自動車道路利用料の従量型課金 (PAYG：Pay As You Go)...Report Details • Do you need definitive automotive pay as you go market data? • Succinct automotive pay as you go market analysis? • Technological insight? • Clear competitor analysis? • Actionable business recommendations? Read on to discover how this definitive report can transform your own research and save you time. Several mergers and acquisition from industry leaders such as Kapsch and Thales Group has led Visiongain to publish this timely report. The automotive pay as you go market was valued at USD 7.34 billion in 2018, increased traffic on highways and increased infrastructure spending by major countries around the...
  • テレメディスンデバイス（遠隔医療機器）の世界市場2018-2028
    VGAIN803044 / visiongain / 2018年2月 / visiongain社が発行した当調査レポートでは、テレメディスンデバイス（遠隔医療機器）の世界市場について調査・分析し、テレメディスンデバイス（遠隔医療機器）の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・テレメディスンデバイス（遠隔医療機器）のイントロダクション ・テレメディスンデバイス（遠隔医療機器）：世界における市場2017-2028 ・テレメディスンデバイス（遠隔医療機器）：デバイス種類別 ・主要国における市場2017-2028 ・企業プロファイル ・品質分析 ・結論 ・用語集...The Global Telemedicine Devices market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to the delivery of healthcare. It is estimated that in 2025, an estimated 1.56 billion adults will be living with hypertension. Telemedicine can help in better management of these diseases as well as help to reduce associated cost. The sickness, disability or death associated with chronic disease can be avoided through preventive measures and use of telemedicine. Moreover, when an older person...
  • バイオシミラーモノクロナール抗体 (MAb)の世界市場2018-2028
    VGAIN803046 / visiongain / 2018年2月 / visiongain社が発行した当調査レポートでは、バイオシミラーモノクロナール抗体 (MAb)の世界市場について調査・分析し、バイオシミラーモノクロナール抗体 (MAb)の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・バイオシミラーモノクロナール抗体(MAb)のイントロダクション ・世界におけるバイオシミラーモノクロナール抗体(MAb)市場2018-2028 ・個別バイオシミラーモノクロナール抗体(MAb)商品：上市薬・パイプライン薬2018-2028 ・主要国におけるバイオシミラーモノクロナール抗体(MAb)市場2018-2028 ・バイオシミラーモノクロナール抗体(MAb)市場における主要企業 ・バイオシミラーモノクロナール抗体(MAb)市場の品質分析...The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 204-page report you will receive 72 tables and 74 figures– all unavailable elsewhere. The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay...
  • 分散型光ファイバーセンシング (DFOS)の世界市場2018-2028
    VGAIN803016 / visiongain / 2017年12月 / visiongain社が発行した当調査レポートでは、分散型光ファイバーセンシング (DFOS)の世界市場について調査・分析し、分散型光ファイバーセンシング (DFOS)の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・分散型光ファイバーセンシング(DFOS)市場のイントロダクション ・世界における分散型光ファイバーセンシング(DFOS)市場2018–2028 ・分散型光ファイバーセンシング(DFOS)市場ダイナミクス ・分散型光ファイバーセンシング(DFOS)産業分析 ・分散型光ファイバーセンシング(DFOS)市場：種類別2018-2028 ・分散型光ファイバーセンシング(DFOS)市場：作動原理別2018-2028...Visiongain has calculated that the global Distributed Fibre Optic (DFOS) Sensing market will see a capital expenditure (CAPEX) of $924.91 mn in 2018. Read on to discover the potential business opportunities available. Distributed Fibre Optic Sensing (DFOS) is a monitoring and sensing solution that utilises the backscatter of light pulses directed down a Fibre Optic cable, to monitor temperature, acoustics, and strain affecting that cable. The application of distributed fibre optic sensors in various fields proves the enormous assistance in curbing the real-world catastrophes in their respective fields. Distributed fibre optics sensing has been widely used in challenging and harsh...
  • 集光型太陽熱発電 (CSP)の世界市場2018-2028
    VGAIN803026 / visiongain / 2018年2月 / visiongain社が発行した当調査レポートでは、集光型太陽熱発電 (CSP)の世界市場について調査・分析し、集光型太陽熱発電 (CSP)の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・集光型太陽熱発電(CSP)市場のイントロダクション ・世界における集光型太陽熱発電(CSP)市場2018-2028 ・世界における集光型太陽熱発電(CSP)市場：技術別予測2018-2028 ・主要国における集光型太陽熱発電(CSP)市場予測2018-2028 ・集光型太陽熱発電(CSP)市場のSWOT分析2018-2028 ・集光型太陽熱発電(CSP)市場における主要企業...Visiongain has calculated that the global Concentrated Solar Power (CSP) Market will see a capital expenditure (CAPEX) of $12,568 mn in 2018. Read on to discover the potential business opportunities available. The Concentrating solar power (CSP) is a power generation technology which uses mirrors to concentrate energy from the sun which drives steam turbines and generators to produce electricity. The four major CSP technologies comprise of a parabolic trough, linear Fresnel reflector, solar tower and solar dish. The CSP technology has an ability to store energy so as to provide electricity as and when required and thus help reduce the...
  • 小規模液化天然ガス (LNG)の世界市場2018-2028
    VGAIN803023 / visiongain / 2018年2月 / visiongain社が発行した当調査レポートでは、小規模液化天然ガス (LNG)の世界市場について調査・分析し、小規模液化天然ガス (LNG)の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・小規模液化天然ガス(LNG)市場のイントロダクション ・世界における小規模液化天然ガス(LNG)市場の概要2018-2028 ・小規模液化天然ガス(LNG)サブマーケット市場予測2018-2028 ・主要国における小規模液化天然ガス(LNG)市場予測2018-2028 ・小規模液化天然ガス(LNG)のPESTEL分析2018-2028 ・専門家の見解...Visiongain has calculated that the global Small Scale Liquefied Natural Gas (LNG) Market will see a capital expenditure (CAPEX) of $4,627.8 mn in 2018. Read on to discover the potential business opportunities available. Small Scale LNG is used to supply small or isolated demand centers not connected to pipeline infrastructure, small scale LNG infrastructure is now increasingly deployed to cater to the growing demand for LNG as a transport fuel. Natural gas can be transported from gas production centers to consumption centers in the form of liquefied natural gas (LNG) through ships and pipelines. Natural gas can be transported in...
  • ガス絶縁変電所 (GIS)の世界市場2018-2028
    VGAIN803022 / visiongain / 2018年2月 / visiongain社が発行した当調査レポートでは、ガス絶縁変電所 (GIS)の世界市場について調査・分析し、ガス絶縁変電所 (GIS)の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・ガス絶縁変電所(GIS)市場のイントロダクション ・世界におけるガス絶縁変電所(GIS)市場2018-2028 ・世界におけるガス絶縁変電所(GIS)市場：電圧別予測2018-2028 ・主要地域と各国におけるガス絶縁変電所(GIS)市場予測2018-2028 ・ガス絶縁変電所(GIS)市場のSWOT分析2018-2028 ・ガス絶縁変電所(GIS)市場のPEST分析2018-2028...Visiongain has calculated that the global Gas Insulated Substation (GIS) Market will see a capital expenditure (CAPEX) of $26,069 mn in 2018. Read on to discover the potential business opportunities available. The concept of the gas insulated substation was introduced in 1920 when oil was used as the insulating medium in the system. The use of oil was replaced by the compressed air, and different gases are owing to increased research and development in the industry. A substation is considered as one of the vital elements of power system infrastructure. It is developed to transform high electrical voltage to low...
  • 軍用EO/IRシステム (電気光学/赤外線システム)の世界市場2018-2028
    VGAIN803015 / visiongain / 2018年1月 / visiongain社が発行した当調査レポートでは、軍用EO/IRシステム (電気光学/赤外線システム)の世界市場について調査・分析し、軍用EO/IRシステム (電気光学/赤外線システム)の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・軍用EO/IRシステム(電気光学/赤外線システム)市場のイントロダクション ・世界における軍用EO/IRシステム(電気光学/赤外線システム)市場2018-2028 ・世界における軍用EO/IRシステム(電気光学/赤外線システム)サブマーケット予測2018-2028 ・主要国における軍用EO/IRシステム(電気光学/赤外線システム)市場予測2018-2028 ・軍用EO/IRシステム(電気光学/赤外線システム)市場のSWOT分析2018-2028 ・専門家の見解...The latest report from business intelligence provider Visiongain offers comprehensive analysis of the global Military Electro-Optical Infrared System market. Visiongain assesses that this market will generate revenues of US$11.65bn in 2018. Now: Russia avenges Hmeimem, Latakia attacks with Krasnopol rounds. This is an example of the EO/IR deployment critical headline that you need to know about - and more importantly, you need to read Visiongain’s objective analysis of how this will impact your company and the industry more broadly. How are you and your company reacting to this news? Are you sufficiently informed? How this report will benefit you Read...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆